Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.54 |
| ▸ | PNP | P00491 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16401839 | 0.86 | MEN1 (0.51) | XDHPNPMEN1KMT2ABLM | |
| SCHEMBL4655346 | 0.83 | PNP (0.62) | XDHPNPBLMUSP2TSHR | |
| SCHEMBL3072984 | 0.83 | PNP (0.51) | XDHPNPMEN1KMT2ABLM | |
| SCHEMBL2385400 | 0.81 | TK1 (0.40) | MEN1KMT2ATSHRTK1 | |
| SCHEMBL7765224 | 0.80 | TK1 (0.57) | XDHPNPMEN1KMT2ABLM | |
| SCHEMBL27541246 | 0.79 | XDH (0.58) | XDHPNPMEN1KMT2ABLM | |
| SCHEMBL5694190 | 0.79 | XDH (0.60) | XDHPNPBLMNOS1USP2 | |
| SCHEMBL5860317 | 0.78 | PNP (0.59) | XDHPNPMEN1KMT2ABLM | |
| SCHEMBL5694118 | 0.78 | KMT2A (0.42) | MEN1KMT2ALMNASMN1; SMN2HIF1A | |
| SCHEMBL1740464 | 0.77 | XDH (0.57) | XDHPNPBLMUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | claimed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | claimed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | claimed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | claimed |
| CN-117721110-A | Antisense nucleic acid | 日本新药株式会社 | 2024-03-19 | — | — | CN | disclosed |
| CN-107881175-B | Antisense nucleic acid | 日本新药株式会社 | 2022-05-13 | — | — | CN | disclosed |
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2018-12-20 | — | — | US | disclosed |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | disclosed |
| US-20140038181-A1 | CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION | TRILINK BIOTECHNOLOGIES, INC. | 2014-02-06 | — | — | US | disclosed |
| WO-2012094343-A1 | CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION | TRILINK BIOTECHNOLOGIES (US) | 2012-07-12 | — | — | WO | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, FBP1, PNKP | XDH 2594/4885PNP 35/4885MEN1 724/4885 |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | XDH 2883/4885PNP 43/4885MEN1 873/4885 |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, TYMP, PAICS | XDH 2883/4885PNP 43/4885MEN1 873/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | XDH 998/4885PNP 206/4885MEN1 467/4885 |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | XDH 2883/4885PNP 43/4885MEN1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.